Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET
Company Participants
Juli Miller – Head-Investor Relations
Adrian Rawcliffe – Chief Executive Officer
Gavin Wood – Chief Financial Officer
Helen Tayton-Martin – Chief Business Officer
John Lunger – Chief Patient Supply Officer
Elliot Norry – Chief Medical Officer
Cintia Piccina – Chief Commercial Officer
Conference Call Participants
Marc Frahm – Cowen and Company
Tony Butler – ROTH Capital
Faisal Khurshid – SVB Securities
Nick Abbott – Wells Fargo
Mara Goldstein – Mizuho
Operator
Good morning and thank you for standing by. Welcome to the First Quarter 2022 Adaptimmune Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Juli Miller, Head of Investor Relations. Please go ahead.
Juli Miller
Good morning and welcome to Adaptimmune's conference call to discuss our first quarter 2022 financial results and business updates. I would ask you to review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. Adrian Rawcliffe, our Chief Executive Officer; and Gavin Wood, our Chief Financial Officer, are here with me for the prepared portion of the call. Other members of our management team will be available for Q&A.
With that, I'll turn the call over to Adrian Rawcliffe. Ad?
Adrian Rawcliffe
Thank you, Juli, and thank you everyone for joining us. Adaptimmune's ambition is to transform the lives of people with cancer by discovering, developing and delivering cell therapies. This is clearly a long-term ambition. But in the short and medium term, we are focused on the delivery of our 2-2-5-2 strategy. And this year, our focus is specifically on four clear areas: file the BLA for afami-cel, continue building our MAGE-A4 franchise, scale up our manufacturing capabilities and progress our allogeneic products towards the clinic.
In the first quarter, we have executed well across all four areas. We are making good progress towards the submission of our BLA for our first product, afami-cel, for the treatment of synovial sarcoma. At ASCO next month, we will present pooled analysis from patients with synovial sarcoma from across our trials with afami-cel, with a full update on the SPEARHEAD-1 trial planned for CTOS later this year. Secondly, our MAGE-A4 franchise is expanding with a SURPASS family of clinical trials using our next-generation SPEAR T-cells targeting MAGE-A4. We have continued to recruit steadily in the Phase I SURPASS trial and we are planning a data update at ESMO this year.